surmount-1 trial tirzepatide non-diabetic obesity weight loss reduction over time in tirzepatide‐treated participants by early weight response: Post hoc analysis in SURMOUNT‐1 - Ard - 2025 - Diabetes, and Metabolism SURMOUNT 1 // Three-Year Obesty

Scientists have been closely studying this association as more people turn to these widely prescribed drugs for weight management

By understanding how Ozempic face aging accelerates facial hollowing, we can guide you through a proactive partnership to protect your natural look

Call (800) 675-8556 or contact us online to get started

Drinking fluids regularly, eating small, balanced meals, and avoiding long gaps without food can help reduce headaches

George, Utah *Educational Disclosure: The educational information on this page is based on peer-reviewed research and clinical trial data from FDA-approved semaglutide and tirzepatide products (such as Wegovy, Ozempic, Zepbound, and Mounjaro)

www.belugahealth.com Supporting Medical Team: Dr